Bayer's 2018 Financial Forecast Hit By Manufacturing Woes
Executive Summary
Bayer's failure to comply with good manufacturing practice guidelines at a production site in Germany will impact supply of medicines in 2018, shaving millions from its financial forecast for the year ahead.
You may also be interested in...
Bayer In FDA's Bad Books Over Facility Failures
Not for the first time this decade, the German major has been warned by the US FDA about its manufacturing processes and sorting out the problems could affect supplies of some big-selling products such as the blood pressure treatment Adalat and the erectile dysfunction drug Levitra.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.